SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/510DA6EBB103FFCE3D8DF157A43285CA2A155C498BD69D4F3BC5801B9FB3E9C4528BFDF4A8C2A7C1DD1383B91EAC7D71>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/510DA6EBB103FFCE3D8DF157A43285CA2A155C498BD69D4F3BC5801B9FB3E9C4528BFDF4A8C2A7C1DD1383B91EAC7D71
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/510DA6EBB103FFCE3D8DF157A43285CA2A155C498BD69D4F3BC5801B9FB3E9C4528BFDF4A8C2A7C1DD1383B91EAC7D71
http://www.w3.org/2000/01/rdf-schema#comment
"Our results suggest that the addition of bevacizumab to neoadjuvant and adjuvant chemotherapy does not provide clinical benefit to patients with non-metastatic HER2-negative inflammatory breast cancer."
xsd:string
http://purl.uniprot.org/uniprot/#_8E215FFEC3C49F65C3B70ACCB53E580749C45B98E9693E91379EF410CA398B34470BB3D469627B4789CD117B765AFBF5
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/510DA6EBB103FFCE3D8DF157A43285CA2A155C498BD69D4F3BC5801B9FB3E9C4528BFDF4A8C2A7C1DD1383B91EAC7D71
http://purl.uniprot.org/uniprot/F5H1T4
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/510DA6EBB103FFCE3D8DF157A43285CA2A155C498BD69D4F3BC5801B9FB3E9C4528BFDF4A8C2A7C1DD1383B91EAC7D71
http://purl.uniprot.org/uniprot/#_F5H1T4-mappedCitation-27032301
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/510DA6EBB103FFCE3D8DF157A43285CA2A155C498BD69D4F3BC5801B9FB3E9C4528BFDF4A8C2A7C1DD1383B91EAC7D71